Farnesyltransferase inhibitor

Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

Retrieved on: 
Tuesday, July 6, 2021
Drugs, Health, Orphan drugs, Chloroarenes, Imidazoles, Tipifarnib, Farnesyltransferase inhibitor, Oncology, Head and neck cancer, Ras GTPase, Squamous cell carcinoma, HRAS

Tipifarnib is Kuras farnesyl transferase inhibitor drug candidate currently in a registration-directed trial as a monotherapy in patients with HRAS mutant HNSCC.

Key Points: 
  • Tipifarnib is Kuras farnesyl transferase inhibitor drug candidate currently in a registration-directed trial as a monotherapy in patients with HRAS mutant HNSCC.
  • Combining tipifarnib with alpelisib has the potential to provide a clinically meaningful increase in anti-tumor activity compared to when inhibiting either pathway alone, said Stephen Dale, M.D., Chief Medical Officer of Kura Oncology.
  • We believe this clinical collaboration will enable us to potentially expand the use of tipifarnib to a significantly higher percentage of patients with advanced HNSCC.
  • Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide, accounting for more than 500,000 new cases each year.

Proceeds from Priority Review Voucher Sale Will Fund Search for Cure for the Rapid Aging Disease Progeria

Retrieved on: 
Monday, November 23, 2020
Progeria Research Foundation, Senescence, Progeria, Sam Berns, PRF, Farnesyltransferase inhibitor, Farnesyltransferase, Berns, FTI, Priority review, Clinical medicine, Health

PEABODY,Mass., Nov. 23, 2020 /PRNewswire/ --The Progeria Research Foundation (PRF) today announced that it will receive half of the net proceeds of the sale of a Priority Review Voucher (PRV).

Key Points: 
  • PEABODY,Mass., Nov. 23, 2020 /PRNewswire/ --The Progeria Research Foundation (PRF) today announced that it will receive half of the net proceeds of the sale of a Priority Review Voucher (PRV).
  • Zokinvy is a farnesyltransferase inhibitor (FTI) that has shown survival benefit in children with Progeria.
  • The Progeria Research Foundation (PRF) was established in 1999 by the family of Sam Berns, a child with Progeria.
  • PRF is the only non-profit organization solely dedicated to finding treatments and the cure for Progeria and its aging-related conditions, including heart disease.

Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas

Retrieved on: 
Tuesday, March 3, 2020
RTT, Medicine, Medical specialties, Health, Anatomical pathology, Cancer, Tipifarnib, Farnesyltransferase inhibitor, Lymphoma, Peripheral T-cell lymphoma, T-cell lymphoma, Head and neck cancer

This important designation from the FDA comes just two months after tipifarnib was awarded Fast Track for the treatment of patients with HRAS mutant head and neck squamous cell carcinomas (HNSCC), said Bridget Martell, M.A., M.D., Acting Chief Medical Officer of Kura Oncology.

Key Points: 
  • This important designation from the FDA comes just two months after tipifarnib was awarded Fast Track for the treatment of patients with HRAS mutant head and neck squamous cell carcinomas (HNSCC), said Bridget Martell, M.A., M.D., Acting Chief Medical Officer of Kura Oncology.
  • Peripheral T-cell lymphomas compromise up to 20% of all aggressive non-Hodgkin lymphomas and consist of many different subtypes of fast-growing lymphomas, representing approximately 20,000 incident cases per year worldwide.
  • Kura Oncologys lead drug candidate, tipifarnib, is a potent, selective farnesyl transferase inhibitor in-licensed from Janssen in December 2014.
  • Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.

First-Ever Treatment for Rare, Rapid-Aging Disease Progeria Submitted in New Drug Application to the FDA

Retrieved on: 
Tuesday, December 17, 2019
Senescence, Branches of biology, Organic compounds, Chemical compounds, Genodermatoses, Progeria, Chloroarenes, Farnesyltransferase inhibitor, Lonafarnib, Progeroid syndromes, HGPS, HGP

Lonafarnib, a farnesyltransferase inhibitor (FTI), has demonstrated extended survival in children and young adults with Hutchinson-Gilford Progeria Syndrome (HGPS), or Progeria, an ultra-rare and fatal disease that causes premature aging in children.

Key Points: 
  • Lonafarnib, a farnesyltransferase inhibitor (FTI), has demonstrated extended survival in children and young adults with Hutchinson-Gilford Progeria Syndrome (HGPS), or Progeria, an ultra-rare and fatal disease that causes premature aging in children.
  • Without treatment, children with Progeria die of heart disease at an average age of 14.5 years.
  • Since 2007, PRF has funded and led four clinical trials to study lonafarnib's effect on Progeria, treating children from over 30 countries.
  • A rolling NDA for the lonafarnib submission allows completed portions to be submitted and reviewed by the FDA on an ongoing basis.

NetNoggin® releases exploratory analysis "Alzheimer's Recent Drug Failures"

Retrieved on: 
Wednesday, October 2, 2019
Neuroscience, Psychiatry, Learning, Abnormal psychology, Alzheimer's disease, Dementia, Psychiatric diagnosis, RTT, Farnesyltransferase inhibitor, Analysis

In response to news regarding failed clinical trials, caregivers are posting responses claiming this news makes them "depressed' and "pessimistic".

Key Points: 
  • In response to news regarding failed clinical trials, caregivers are posting responses claiming this news makes them "depressed' and "pessimistic".
  • Results from NetNoggin's analysis also show growing concern that the amyloid hypothesis may be the wrong target and other mechanisms should be considered.
  • The community suggests the following next steps:
    Explore the failed cancer drug, farnesyltransferase inhibitors, for Alzheimer's
    Visit https://netnoggin.net/exploratory-analysis to request the full exploratory analysis.
  • NetNoggin has expertise in market research; commercial, market, and clinical development; and communications to provide reliable research, presentations, and workshops.

Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan

Retrieved on: 
Wednesday, February 6, 2019
Medical specialties, RTT, Medicine, Chemistry, Infectious causes of cancer, Hepatotoxins, Hepatitis, Ureas, Viral hepatitis, Hepatitis D, Ritonavir, Farnesyltransferase inhibitor

With the grant of these new European and Japanese patents, lonafarnib boosted with ritonavir has now obtained patent protection with claims covering treatment with lonafarnib boosted with ritonavir in key major pharmaceutical markets including the U.S., Europe, and Japan.

Key Points: 
  • With the grant of these new European and Japanese patents, lonafarnib boosted with ritonavir has now obtained patent protection with claims covering treatment with lonafarnib boosted with ritonavir in key major pharmaceutical markets including the U.S., Europe, and Japan.
  • Lonafarnib is a first-in-class, oral farnesyl transferase inhibitor in Phase 3 development for the treatment of hepatitis delta virus (HDV) infection.
  • "This method of use patent covers lonafarnib boosted with ritonavir for the treatment of hepatitis delta virus infection, including specific doses and durations that we anticipate will appear on the first approved label," said David Cory, President and CEO of Eiger.
  • Hepatitis Delta is caused by infection with the hepatitis delta virus and leads to the most severe form of viral hepatitis.